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Abstract 
Colorectal cancer is a leading cause of death from cancers worldwide in both men and 
women. The highest frequency is seen in Australia and Western Europe. Epidemiologic 
studies have shown that environmental factors such as diet both promote and inhibit the 
development of colon cancer. The “western style diet” typically consists of high amounts of 
fat and small amounts of vitamin D and calcium. Vitamin D is assumed to have a protective 
effect against colon cancer due to its effect on cell proliferation, angiogenesis, apoptosis, 
epithelial differentiation, inflammation and detoxification metabolism in cultured human 
colorectal cancer cells. Retinol (animal derived vitamin A) may decrease the positive effect of 
vitamin D by acting as an antagonist. This has been shown in studies of both rats and 
humans with regards to bone formation. The antagonistic effect is little studied with respect 
to colon cancer.  
In order to exert some effects in the nucleus, both the vitamin D receptor (VDR) and the 
retinoic acid receptor family (RAR) bind to DNA response elements as heterodimers with the 
retinoid X receptor (RXR). This makes up at least one link between pathways of actions for 
both vitamin A and vitamin D, and thus antagonistic effects due to competition for RXR have 
been proposed. Therefore, interactions of 1,25(OH)2D3 , active metabolite of vitamin D and 
all-trans retinoic acid (ATRA), active metabolite of vitamin A was studied  in the human 
colorectal cell line HT-29 APC. The study focused mainly on expression of VDR and RXRα, but 
also on possible effects with respect to necrosis, apoptosis, cell cycle alternations and 
release of the inflammatory marker interleukin -8 (IL -8).  
No significant increase in VDR was seen in HT-29 APC cells exposed to 1,25(OH)2D3, but a 
tendency to increase was seen in cells exposed to the highest concentration (10-5 M). The 
tendency to increase was not seen in cells exposed to combinations of 1,25(OH)2D3 and 
ATRA. Surprisingly, treatments with 10-9 M and 10-7 M 1,25(OH)2D3  revealed significant 
lower levels of RXRα in HT-29 APC compared to control cells. Such effects was not seen in 
cells treated with 10-5 M 1,25(OH)2D3 alone, ATRA alone, or combinations of 1,25(OH)2D3 and 
ATRA. The results indicate that HT-29 APC cells probably have the ability to regulate the 
expression of RXRα, and this may depend on the amount of ligands present. However, an 
antagonistic effect of vitamin A on vitamin D due to competition for RXRα can neither be 
confirmed nor excluded. This is illustrated by the lack of increase in the level of RXRα in cells 
exposed to combinations of 1,25(OH)2D3 and ATRA compared to unexposed cells, or to cells 
exposed to 1,25(OH)2D3  and ATRA alone. 
No effects were seen in HT-29 APC with regards to necrosis, apoptosis, cell cycle alternations 
or release of IL -8 in any of the treatment groups. This may be attributed to differences 
between cell lines with respect to cell specific proteins and various mutations in the genes of 
different cancer cell lines. 
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1. Introduction 
1.1 Antagonistic effects of vitamin A on vitamin D and the development of 
colon cancer - reasons for concern 
Vitamin D is necessary for normal bone metabolism (Cranney et al. 2007). In addition, poor 
vitamin D status is suggested as a contributing factor to the development of a number of 
other conditions including multiple sclerosis (Goldberg et al. 1986; Myhr 2009),diabetes 
(Hypponen et al. 2001) and cancer (Garland et al. 2009; Gorham et al. 2005; Platz et al. 
2000). Colorectal cancer (CRC) is the third most frequent malignancy in men, and second in 
women. It was the fourth leading cause of death from cancer worldwide in 2008 with 1 233 
000 cases diagnosed and 608 000 deaths. The highest frequency is seen in Australia and 
Western Europe (Ferlay et al. 2010). Epidemiological studies show that diet and 
environmental factors both promote and inhibit the development of colon cancer. The 
“western style diet” typically consists of high amounts of fat and small amounts of calcium 
and vitamin D (Erdelyi et al. 2009). Vitamin D is assumed to have a protective effect against 
colon cancer. This has been reported in several studies where vitamin D intake, or serum 
concentration of 25-hydroxyvitamin D (25(OH)D) have been studied, both in vitro and in 
animal models (Giovannucci 2005; Gorham et al. 2005; Grant and Garland 2004). Further 
research suggests that high serum levels of 25(OH)D at the time of diagnosis and initiation of 
therapy, improves prognosis for several types of cancer, among them colorectal cancer 
(Moan et al. 2005; Robsahm et al. 2004).  
Retinol (vitamin A derived from animal sources) may decrease the positive effect of vitamin 
D by acting as an antagonist. This has been shown for bone formation in both rats (Lind et al. 
2006; Rohde and DeLuca 2005) and humans (Johansson and Melhus 2001). Previously, cod 
liver oil contained high concentrations of retinol, which has been suggested as a cause of the 
negative correlation between the intake of cod liver oil at young age, and bone mineral 
density in women (Forsmo et al. 2008). The antagonistic effect is little studied for the 
development of colon cancer, but a study by Hetland et al. in 2009 showed that mice given a 
diet with continuous high intake of retinol had increased number of tumors in the intestine. 
This was surprising, because retinol is traditionally thought to be potentially protective 
against cancer. In male mice, the effect of retinol was regardless of vitamin D intake, but in 
females, the effect of retinol was significantly enhanced by low intake of vitamin D in the 
diet (Hetland et al. 2009).  
In vivo, retinol is converted to retinoic acid, which is the active form of vitamin A. Retinoic 
acid binds to retinoic acid receptor (RAR) and retinoid X receptor (RXR). RXR forms 
heterodimers with several other nuclear receptors such as vitamin D receptor (VDR) and 
thyroid receptor. In order for vitamin D to be able to exert some effects in the nucleus, VDR 
must be activated and form a complex with RXR. The activated complex binds to a vitamin D 
response element (VDRE) located in the promoters of particular genes. Using nuclear 
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proteins that act as co-activators, RNA polymerase II is activated and transcription of DNA to 
produce mRNA starts (Lamprecht and Lipkin 2003). One possible mechanism for the 
antagonistic effect of vitamin A on vitamin D is therefore proposed to be competition for the 
same nuclear receptor (RXR)(Haussler et al. 1997).  
 
1.2 Cancer 
According to the International Agency for Research on Cancer (IARC) of the World Health 
Organization (WHO), there were 32.600.000 people living with cancer and 8.200.000 deaths 
from cancer worldwide in 2012 (Ferlay et al. 2014). 
There are more than 100 distinct types of cancer, and subtypes of tumors can be found 
within the same organ (Hanahan and Weinberg 2000). In the article “Hallmarks of Cancer” 
published in 2000, Hanahan and Weinberg argued that the complexity of cancer can be 
reduced to the manifestation of six essential alterations in cell physiology that together 
dictates malignant growth (figure1.1). The six hallmarks are: 
1. Self-sufficiency in growth signals. Normal cells needs mitogenic growth signals to 
move from a quiescent state to an active proliferate. Many of the oncogenes act 
by mimicking normal growth signaling. 
2. Insensitivity to antigrowth signals. In normal tissue, multiple antiproliferative 
signals operate to maintain cellular quiescence and tissue homeostasis. Many and 
perhaps all antiproliferative signals are funneled through the tumor suppressor 
gene retinoblastoma (pRb) and its relatives p107 and p130 (Weinberg 1995). 
Disruption of pRb pathway renders cells insensitive to antigrowth factors that 
normally operate along this pathway to block advance through the G1 phase of 
the cell cycle. 
3. Evasion of programmed cell death (apoptosis). Intracellular sensors monitor 
abnormal behavior, and effectors, which cause apoptosis (Evan and Littlewood 
1998). Resistance to apoptosis can be acquired by cancer cells in many ways, but 
the most commonly occurring is through loss of the proapoptotic regulator p53. 
Inactivation of its product can be seen in more than 50 % of human cancers 
(Harris 1996). 
4. Limitless replicative potential. Observation of cultured cells indicates that normal 
human cell types have the capacity to replicates themselves 60-70 times. This has 
been attributed to the inability of the DNA polymerases to replicate the 3’ ends of 
chromosomal DNA during each S phase, progressively shortening the telomeres. 
This leads to unprotected chromosomal ends which, almost inevitably, results in 
death of the affected cell (Counter et al. 1992). Telomere maintenance is seen in 
virtually all types of malignant cells (Shay and Bacchetti 1997). The vast majority 
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of them (85% -90 %)  have managed it by up regulating expression of the 
telomerase enzyme (Bryan and Cech 1999). 
5. Sustained angiogenesis (the growth of new blood vessels). Because of the need 
for oxygen and nutrients, virtually all cells reside within 100 µm from a capillary 
blood vessel. In order to progress to a larger size, an initial neoplasia needs to 
develop angiogenic ability (Bouck et al. 1996). Tumors appear to activate the 
angiogenic switch by changing the balance of angiogenesis inducers and 
inhibitors (Hanahan and Folkman 1996). The mechanisms underlying these shifts 
remain incompletely understood. 
6. Tissue invasion and metastasis. The capability of distant settlements of tumor 
cells (metastases) is seen in 90 % of human cancer deaths (Sporn 1996). The 
process is immensely complex, and the underlying genetic and biochemical 
determinants remain incompletely understood. 
 
 
 
 
 
 
Figure 1.1 Illustrates the six fundamental alternations in cell physiology needed to develop any type of cancer 
(Hanahan and Weinberg 2000). 
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1.2.1 Colorectal cancer 
By the age of 70, at least 50% of the Western population develops a colorectal tumor, and in 
about 1 of 10 of these individuals, there will be a progression to malignancy (Kinzler and 
Vogelstein 1996).  Approximately 3-5 % of the CRC cases in humans are due to inherited 
syndromes as familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal 
cancer (HNPCC), but the majority of colorectal cancers seems to occur sporadic (Narayan 
and Roy 2003). Epidemiological studies show that people who move from low to high risk 
areas adopt the higher risk level, indicating that environmentally factors, and especially diet, 
are of great importance in the development of CRC (Boyle and Levin 2008).  Mice given a 
western style diet that is high in fat and low in vitamin D, calcium and folate sporadic 
develops colon tumors (Newmark et al. 2001; Yang et al. 2008). Perhaps even more 
interestingly, tumor development in mice can be suppressed by the reintroduction of 
vitamin D and calcium (Newmark et al. 2009).  
 
1.3 Vitamin D 
Vitamin D is the precursor to a fat-soluble steroid hormone that has many functions in the 
body and regulates more than 900 genes in humans (Wang et al. 2005). Vitamin D is 
produced in the skin when exposed to sunlight, and therefore it may be more correct to call 
it a pro-hormone. However, when the sun exposure of the skin is not sufficient to produce 
sufficient vitamin D, the intake of dietary vitamin D is necessary to maintain adequate status, 
which makes the term vitamin correct. The active form of vitamin D, 1α,25-dihydroxyvitamin 
D3 (1,25(OH)2D3), is formed in a multistep pathway (figure 1.2). The skin contains precursor 
7-dehydrocholesterol which upon exposure to UVB radiation is converted to pre-vitamin D3. 
After sun exposure, or absorption by intestines from dietary sources, the pre-vitamin is 
hydroxylated first the liver and thereafter in the kidney before the 1,25(OH)2D3 is 
transported in the blood bound to a vitamin-D-binding protein (DBP)(Lamprecht and Lipkin 
2003; Rhieu et al. 2014).  
The precise molecular mechanism of 1,25(OH)2D3 signaling is not fully understood. 
Lamprecht and Lipkin suggests that the actions are mediated by 1,25(OH)2D3 binding to a 
nuclear high affinity receptor (VDR) in complex with the RXR. There are three known 
subtypes of RXR; α, β and γ. RXRα is shown to be the functionally most important in VDR 
heterodimerization. The activated VDR-RXR complex binds to a vitamin D response element 
located in the promoter of genes. The binding of the VDR-RXR complex recruits nuclear 
proteins that act as co-activators of polymerase II and DNA transcription. They also suggests 
that 1,25(OH)2D3 might bind to a membrane bound vitamin D receptor (mVDR) as well 
(figure 1.2)(Lamprecht and Lipkin 2003). Fleet et al. describes that some data demonstrates 
that heterodimerization of the VDR-RXR complex is required for migration of the VDR-RXR-
1,25(OH)2D3  complex from the cytoplasm to the nucleus, but that new data using ChIP-seq 
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(chromatin immunoprecipitation followed by DNA sequencing), show that RXR can be bound 
to VDR binding sites prior to VDR recruitment to this sites (Fleet et al. 2012). Regardless of 
which mechanism, when the RXR-VDR heterodimer is bound to DNA, protein complexes are 
recruited that alter the chromatin structure. 
 
 
 
Figure 1.2  Illustrates the multistep pathway forming 1,25(OH)2D3  in vivo, and proposed modes of 1,25(OH)2D3 
signaling (Lamprecht and Lipkin 2003). 
 
Garland and Garland were the first who published a paper suggesting an inverse relationship 
between latitude (solar radiation) and colorectal cancer mortality in 1980 (Garland and 
Garland 1980). Since then, there are published large amounts of literature that examines the 
relationship between vitamin D status and incidence of colorectal cancer. The proposed anti-
tumoral actions of 1,25(OH)2D3 includes inhibition of cell proliferation and angiogenesis, 
sensitizing to apoptosis, induction of epithelial differentiation and detoxification metabolism 
(figure 1.3).  
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Figure 1.3 Overview over the anti-tumoral actions of 1,25(OH)2D3 (Pereira et al. 2012). 
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1.4 Vitamin A 
Retinol (animal derived vitamin A) is converted to retinaldehyde and then to all-trans 
retinoic acid (ATRA) by way of two oxidation steps (figure 1.4). ATRA is the active metabolite 
of retinol that regulates retinol-regulated gene transcription. 9-cis-retinoic acid is another 
biologically active ligand for the RAR-RXR complex, but the circulating levels are much lower 
than those of all-trans retinoic acid. The biological effect of the isomerization between the 
two is not fully understood (Lee et al. 2004). Retinoic acid (RA) is well known for its 
importance in mammalian development (Wohl and Weiss 1998),  and it is required for 
vision. (Maeda et al. 2006) . Moreover, RA is routinely used for the treatment of lymphoma 
(Duvic and Cather 2000) and leukemia (Huang et al. 1988).  
 
Figure 1.4 Metabolic pathway of retinol yielding the metabolic active metabolite ATRA.  The illustration is 
modified from a figure made by Perlmann (Perlmann 2002).  
RA cell signaling acts through a group of receptors called retinoic acid receptors (RAR). RAR is 
not active in its monomeric form, but forms heterodimeric proteins with retinoid X receptor 
(RAR:RXR) (Chambon 2005) (figure 1.5). Hence, the requirement of RXR makes up at least 
one link between the vitamin A and vitamin D responsive system (Rohde and DeLuca 2005). 
 
 
Figure 1.5 Illustrates ATRA cell signaling pathway. Notice that RXR is required (from www.sigmaaldrich.com). 
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1.5 Apoptosis and necrosis  
Tumors result from an imbalance between cell birth and cell death. Programmed cell death 
(PCD) is a process where cells “commit suicide” at a specific point in the development 
process, hence the term “programmed”. Because most examples of PCD are via apoptosis, 
the two names are interchangeably used in many studies, but it is important to clarify that 
apoptosis is only one type of PCD (Chipuk and Green 2005). Apoptosis is classically 
characterized by its morphology; cell shrinkage and formation of apoptotic bodies that 
phagocytic cells are able to engulf and quickly remove before the contents of the cell is 
released, which can cause damage to surrounding cells (Wyllie et al. 1980). It has been 
estimated that in a human body it is produced approximately 100.000 new cells every 
second, and about as many cells die every second via apoptosis (Fadeel and Orrenius 2005). 
The concept that apoptosis serves as a natural barrier to cancer development has been 
established in numerous studies (Adams and Cory 2007; Evan and Littlewood 1998; Kerr et 
al. 1972). Apoptosis sensitization by 1,25(OH)2D3  in colorectal adenoma and carcinoma cells 
involves up regulation of the pro-apoptotic proteins BAK1, BAX (Diaz et al. 2000)(figure 1.6), 
G0S2 (Palmer et al. 2003) and down regulation of anti-apoptotic proteins BAG-1 (Barnes et 
al. 2005), BCL-2 (figure 1.6) and  BCLXL (Hansen et al. 2001).   
 
 
 
 
Figure 1.6 The active metabolite of vitamin D up regulates expression of the pro-apoptotic proteins BAK and 
BAX that participates in the formation of pores that contributes to the release of the mitochondrion 
cytochrome c. Cytochrome c promotes the complex formation of APAF1 and pro-caspase-9. In turn, activated 
caspase-9 activates caspase-3, leading to apoptotic cell death. 1,25(OH)2D3 can also down regulate expression 
of BCL2, the prototypic anti-apoptotic protein (Lamprecht and Lipkin 2003). 
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Necrosis has historically been viewed as a result of system exhaustion, but cell death by 
necrosis is clearly under genetic control in some instances (Zong and Thompson 2006).  In 
contrast to apoptosis, necrotic cells become bloated and explode, releasing content to the 
local tissue (figure 1.7). As a result necrotic cells can recruit inflammatory cells of the 
immune system. The mission of the inflammatory cells is to remove necrotic debris and limit 
the extent of tissue damage (White et al. 2010). However there are evidence indicating that 
immune inflammatory cells can be actively tumor promoting (Grivennikov et al. 2010). 
 
 
 
 
 
Figure 1.7 Illustrates the differences between apoptosis and necrosis (Scarabelli et al. 2006). 
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1.6 Inflammation 
Inflammation is basically a protective process in which immune cells are triggered to 
neutralize microorganisms and repair tissue damage. Pathologists have long known that 
some tumors are densely infiltrated by immune cells (Dvorak 1986). The immune responses 
were most of all thought to be an attempt from the immune system to eliminate tumors, but 
research the last decade has demonstrated tumor promoting effects from the immune 
system on neoplastic progression (Colotta et al. 2009) by supplying the tumor 
microenvironment with hallmark capabilities of cancer such as growth factors, pro-
angiogenic factors and enzymes that facilitate angiogenesis, invasion and metastasis 
(Karnoub and Weinberg 2006). Furthermore, there are evidence that inflammation in some 
cases is capable of fostering the development of initial neoplasias into fully developed 
cancers (Qian and Pollard 2010). In addition, inflammatory cells can release reactive oxygen 
species (ROS) that are mutagenic for nearby cells, including cancer cells, and thereby 
accelerating their genetic progress towards malignancy (Grivennikov et al. 2010).  
Cytokines are small glycoproteins that act as communication molecules between 
neighboring cells. They can be divided into pro-inflammatory and anti-inflammatory 
molecules by family (Dinarello 2000). In this study, the amount of the pro-inflammatory 
cytokine, interleukin 8 (IL -8) excreted into the medium by cells, were measured. IL -8 is a 
chemo attractant that binds to and activates neutrophils, so that they are drawn towards 
the inflammation site. IL-8 is also known to be a potent promoter of angiogenesis 
(Zarogoulidis et al. 2014). In normal tissue the production of IL -8 is low, but the level may 
rise from 10 to 100 fold by stimulation of the chemokines IL-1β, TNFα, or by an infection 
(Hoffmann et al. 2002). Cellular stress may also provide a significant increase in IL-8.  
The potent anti-inflammatory action of 1,25 (OH)2D3 is seen both in vivo (Froicu et al. 2006) 
and in vitro. In CRC cells treated with IL-1β,   1,25(OH)2D3  is shown to antagonize the NF-κB 
pathway which is responsible for the expression of IL-8. Thus, 1,25(OH)2D3 has the potential 
to be an important regulator of the immune system in the colon as both epithelial and 
immune cells of the gut mucosa express VDR (Sun et al. 2008). 
 
 
1.7 Cell cycle alternations 
There is no doubt that the most fundamental trait of cancer cells involves their ability to 
sustain chronic proliferation (Hanahan and Weinberg 2011). Normal tissue carefully controls 
the production and release of growth-promoting signals. Cancer cells become master of 
their own destinies by deregulating these signals. The cell cycle clock uses a group of kinases 
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called the cyclin-dependent kinases (CDKs) to execute the various steps of the cell cycle 
progression (figure 1.8). 
 
 
 
Figure 1.8 The cell cycle clock and the variety of cyclins/ CDKs needed for the cell to proceed from one phase to 
the next (from Weinberg, The Biology of Cancer, first edition). 
 
The CDKs must bind to a cyclin protein in order to become active. Cyclin A, B and E undergo 
cycles of synthesis and degradation as the cell progresses through the various phases of the 
cell cycle. The rapid degradation of the various cyclins at specific time points ensures that 
the cell cycle clock can move in only one direction (figure 1.9).  
 
 
Figure 1.9 An overview over the synthesis and degradation of cyclins during the cell cycle (from Weinberg, The 
Biology of Cancer, first edition). 
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Cells that enters G1 from mitosis needs serum mitogens continuously until hours before the 
onset of S phase. After passing that point, they become relatively serum independent. This 
transition from dependent to independent is termed the restriction point (R-point) (Pardee 
1989)(figure1.7 and 1.8). By passing the R-point, the cell commits itself to go through the 
mitotic phase (M-phase) even if the cell has major DNA damage or metabolic disturbance 
(Weinberg 1995). A cell that has proceeded through most of the G1 phase encounters the 
guardian of the R point –the retinoblastoma tumor suppressor gene. The retinoblastoma 
protein (pRb) binds and inhibits the E2F transactivation domain (Di Fiore et al. 2013). If the 
conditions are appropriate for going into S-phase, pRb will be phosphorylated by cyclin E-
CDK2 which causes its inactivation and the subsequent release of E2F transcription factors 
that control the expression of banks of genes that is needed for progression from G1 into S-
phase (Weinberg 1995). Disruption of the pRb pathway liberates E2Fs and thereby allows 
cell proliferation and make cells insensitive to antigrowth factors (Hanahan and Weinberg 
2000). Function of pRb can be lost through mutation of its gene. In some DNA virus-induced 
tumors, pRb is destroyed through sequestration by viral oncoproteins, such as E7 
oncoprotein of human papillomavirus (Dyson et al. 1989).  
The growth inhibitory effect of 1,25(OH)2D3 on CRC cells is a result of accumulation of cells in 
the G0/G1 phase. 1,25(OH)2D3 induces expression of p21CIP1 and p27KIP1 that inhibits CDK 2 
and CDK 4 needed for the cell cycle progression at G1. Additionally 1,25(OH)2D3 represses the 
action of cyclins A and F (Evans et al. 1999; Gaschott et al. 2002).  
 
1.8 Cell line used in this study 
In this study, the human colorectal adenocarcinoma cell line HT-29 APC was used. The HT-29 
cell line is widely used for experimental studies because it has many biochemical and 
physiologic features of normal colorectal epithelial cells (von Kleist et al. 1975). VDR 
expression is only present in adenoma tumor tissue, whereas in advanced carcinomas it 
decreases or disappears (Gonzalez-Sancho et al. 2006).  
Mutations of the adenomatous polyposis coli ( APC) tumor suppressor gene is an early event 
found in about 80% of all CRC (Neufeld 2009). The HT-29 cells contain no intact APC gene, 
but two carboxyl-terminal truncated proteins of about 100 kDa and 200 kDa are present. 
Morin et al. transfected the HT-29 cell line with the zinc inducible expression plasmid pSAR-
MT-APC to achieve the expression of full length APC, together with the hygromycin 
resistance vector pCEP (Invitrogen) yielding the cell line HT-29 APC used in this study. (Morin 
et al. 1996).  The cell line is not commercially available, but was a gift to the Norwegian 
Institute of Public health, Division of Environmental Medicine, from Bert Vogelstein. In this 
study, the HT-29 APC cells were cultured without zinc. Thus, the importance of an intact APC 
on the analyzed endpoints was not explored.  
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1.9 Aims of study 
The main goal of this study was to analyze if the levels of VDR and RXRα were influenced 
when cells were exposed to different concentrations of 1,25(OH)2D3, all-trans retinoic acid 
(ATRA), and combinations of ATRA and 1,25(OH)2D3, to clarify whether vitamin A may have 
antagonistic effects on vitamin D by competing for the same nuclear receptor. A human 
colorectal cancer cell line (HT-29 APC) was used. 
1. Are the levels of VDR influenced when cells are exposed to different levels of 
1,25(OH)2D3, or combinations of 1,25(OH)2D3  and ATRA? 
2. Are the levels of RXRα influenced when cells are exposed to different levels of 
1,25(OH)2D3, ATRA or combinations of 1,25(OH)2D3  and ATRA? 
 
To ensure that concentrations of the treatments used on the study didn’t have a toxic effect 
on the cell line, a second aim was to clarify if there were any differences in the proportion of 
necrotic cells. 
3. Will exposure to the concentrations of 1,25(OH)2D3, ATRA or combinations of 
1,25(OH)2D3 and ATRA cause increased proportion of necrotic cells? 
The third aim was to clarify if any of the treatments in the study influenced the proportion of 
apoptotic cells. 
4. Will exposure to 1,25(OH)2D3, ATRA or combinations of 1,25(OH)2D3 and ATRA 
influence the proportion of apoptotic cells? 
 
The fourth aim was to clarify whether any of the treatments used in this study influenced 
cell cycle alternations. 
5. Will exposure of cells to 1,25(OH)2D3, ATRA or combinations of 1,25(OH)2D3 and ATRA  
influence the proportion of cells in G1, S or  G2 phase?  
The fifth aim was to examine if any of the treatments used in this study influenced release of 
the inflammatory marker IL -8. 
6. Will exposure of cells to 1,25(OH)2D3, ATRA or combinations of 1,25(OH)2D3 and ATRA  
influence the proportion IL -8 secreted in the medium? 
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2. Principles of methods used in this study 
2.1 Western blotting 
Western blotting is a widely accepted technique were proteins in a cell lysate is separated 
from one another  according to their size by gel electrophoresis, and then transferred to a 
positively charged nitrocellulose membrane, were specific antibodies are used to detect 
proteins of interest. The technique was first described by Towbin et al (Towbin et al. 1979) in 
1979, and later given the name “western blotting” by Burnette in 1981 (Burnette 1981). 
To prepare proteins for running on a gel, cells and tissues need to be lysed to release the 
proteins of interest. The lysis buffer contains Triton X-100 that creates pores in the cell 
membrane and the content will leak out of the cells. The buffer also contains protease 
inhibitors that prevent proteases to break down proteins. The cell lysate is viscous because 
of the free DNA strands and was therefore sonicated by ultrasound to break the DNA 
strands. 
Test of settings for the sonicator 
The sonicator (BioRuptor plus, Diagenode, Rui Bois Saint-Jean 3, Seraing, BE) used in these 
experiments was recently purchased and had not been used before. The instructions for use 
recommended 5 to 10 cycles of 30 seconds with ultrasound, depending on the cell type. A 
pilot experiment was carried out to test what worked out best for the HT-29 APC cell line. 
In this experiment; 2 x 10-6 cells were seeded in 10 cm2 dishes (Sarstedt) in a total of 10 ml 
medium (McCoy’s) for each dish. The dishes were placed in a CO2 incubator (Seri Cycle) until 
they were 100 % confluent (about 72 hours), and then cells were harvested and lysed the 
same way as described for the main experiments (chapter 3.2). Procedure for protein 
measurements, electrophoresis, blotting and detection of proteins of interest was also done 
similarly as described for the main experiments. The goal was to find the best conditions for 
breakage of DNA strands in HT-29 APC cells. Therefore, histone H1 was chosen to be the 
protein of interest in this experiment. Histones are basic nuclear proteins that are 
responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. 
Nucleosomes consist of approximately 146 bp of DNA wrapped around a histone octamer. 
The chromatin fiber is further compacted through the interaction of a linker histone, H1 (See 
figure 2.1). Anti-Histone H1 antibody (Upstate (Millipore)) was used to detect the protein. 
The results can be seen in figure 2.2  
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Figure 2.1 Showing an illustration of a nucleosome, and the linker histone H1. (picture: http://en.wikipedia.org) 
 
 
                                                 
Figure 2.2 Lane 1 and 2 shows cell lysate treated with the old sonicator (Sonics & Materials, Inc.). Lane 3 and 4 
shows cell lysate treated with the new sonicator (BioRuptor), 3 cycles of 30 seconds. Cell lysates in lane 5 and 6 
have been sonicated 5 cycles of 30 seconds, and cell lysates in lane 7 and 8 have been sonicated 10 cycles of 30 
seconds. 
 
In this experiment, 5 cycles of 30 seconds with ultrasound seemed to give the best results 
for sonication of HT-29 APC cells. This is also within the range of what is recommended in 
the instruction manual. Based on this experiment, all cell lysates in the main experiments 
were sonicated 5 cycles of 30 seconds each.  
 
In order to separate proteins according to their approximate size in a cell lysate by 
electrophoresis, the protein in the samples must be heated with mercaptoethanol, and 
sodium dodecyl sulfate (SDS). Mercaptoethanol removes secondary and tertiary structure 
(e.g. disulfide bonds (S-S) to sulfhydryl groups (SH and SH). When SDS is used with proteins, 
all of the proteins become negatively charged by their attachment to the SDS anions. SDS 
denatures proteins by “wrapping around” the polypeptide backbone and confers a negative 
charge to the polypeptide in proportion to its length. The negative charge on the protein 
enables it to migrate from cathode to the anode during electrophoresis (figure 2.3). The 
running buffer also contains bromophenol blue that serves as a marker showing how far the 
smallest proteins have moved in the acrylamide-gel and glycerol to make samples heavy 
enough to stay in the bottom of wells. 
 
Histone H1 
   1       2     3    4     5     6     7    8   
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Figure 2.3 When the proteins are heated up to over 70 °C with mercaptoethanol and SDS the multidimensional 
structure is broken and the protein becomes denatured. (The illustration is modified from Life, The Science of 
Biology, 7th edition)  
 
 
Gel casting is carried out by an acrylamide / Bis-acrylamide solution being polymerized using 
ammonium persulfate (APS). The reaction is catalyzed by tetramethylethylenediamine 
(TEMED). The gel will then form a grid and the percentage acrylamide is varied according to 
the size of the molecules to be detected. High concentration is used if one should look at 
small molecules, and low concentration when looking at large molecules.  
Access to proteins in the acrylamide gel is limited. In order to detect proteins with 
antibodies, electro blotting of proteins from the gel to a membrane is necessary. A blotting 
“sandwich”, (sponge/paper/gel/membrane/paper/sponge) is submerged in a buffer to which 
an electrical field is applied. The negatively-charged proteins travel towards the positively-
charged electrode, but the membrane stops and binds them. 
By taking advantage of antigen-antibody interactions as in ELISA (chapter 2.4), specific 
proteins can be detected on the membrane. To prevent non-specific background binding of 
the primary and/or secondary antibodies to the membrane (which has a high capacity at 
binding proteins and therefore also antibodies), the membranes needs to be blocked in a 
buffer containing non-fat milk, or bovine serum albumin (BSA) before they are incubated in 
the primary antibody. 
Antibodies, also known as immunoglobulins, are a group of proteins consisting of two heavy 
chains and two light chains (figure 2.4). Though the general structure of all antibodies is very 
similar, a small region at the tip of the protein is a hypervariable region, allowing millions of 
antibodies with slightly different antigen-binding sites to exist. 
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Figure 2.4  An antibody is a large Y-shape protein produced by plasma cells. Each tip of the "Y" of an antibody 
contains a paratope that is specific for one particular epitope on an antigen (from Lehninger, Principles of 
Biochemistry, fifth edition.) 
 
When an antigen is injected to an animal, the immune response of the organism forms many 
different antibodies against the antigen. An antigen contains many epitopes antibodies can 
bind to, but each immune cell can only produce one type of antibody.  
Monoclonal antibodies are made by identical immune cells that are all clones of a unique 
parent cell. They have monovalent affinity, meaning that they bind to the same epitope. A 
problem using monoclonal antibodies is that they may not bind to isomeric forms of a 
protein, and if the sample contains small amounts of the protein of interest, the antibody 
may not bind well enough to be detected.  
A polyclonal antibody is purified serum from animals and contains antibodies from many 
different immune cells that react with different epitopes on the antigen. For that reason, 
polyclonal antibodies provide more cross-reactions and nonspecific binding than a 
monoclonal. 
To detect and quantify VDR and RXRα, polyclonal antibodies were used, and to detect and 
quantify the loading control β-actin, monoclonal anti-β-actin antibody was used during this 
study. 
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2.2 Fluorescence microscopy 
In fluorescence microscopy, the sample itself is the light source. The sample can either be 
fluorescent in its natural form like chlorophyll, or treated with fluorescent chemicals. A 
fluorescent compound absorbs light energy over a range of wavelengths that is specific for 
that compound. The absorption of light causes an electron in the fluorescent compound to 
be raised to a higher energy level. When the excited electron decays to its ground state, 
excess energy is emitted as a photon of light. The transition of energy is called fluorescence 
(BD Biosciences 2000).  In this study the fluorescent dye Hoechst 33342 and the fluorescent 
molecule propidium iodide was used to stain DNA in harvested cells. Hoechst 33342 is a cell-
permeable DNA stain that is excited by ultraviolet light and emits blue fluorescence at 460 to 
490 nm. Propidium Iodide (PI) is not capable of penetrating the cell membrane in viable 
cells, but it binds to DNA by intercalating between the bases in nonviable cells, giving 
necrotic cells a distinctive red color. 
 
 
2.3 Flow cytometry 
A flow cytometer is quite similar to a microscope, but instead of producing an image of the 
cells, it gives a “high throughput “automated quantification of parameters of interest. Flow 
cytometers are able to analyze several thousand particles every second in “real time”, and it 
can isolate and separate particles with specified properties (Chirvi 2008). It is made up of 
three main systems; the fluidic system that transports particles in a stream to the laser beam 
for interrogation, the optics systems which consists of lasers that illuminates particles in the 
laser stream, and the electronics system which converts the detected light signals into 
electronic signals (figure 2.5). The primary laser beam is 488 nm and creates a forward 
scatter which is a signal proportional to the physical size of the particles, and a side scatter 
which describes the particles granularity or internal complexity. A red blood cell has no 
nucleus and few organelles and creates a very small side scatter, while a white blood cell has 
a nucleus and many organelles, and thus forming a higher side scatter signal (Fuchs 
(website)). 
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Figure 2.5 Illustrates the principle of the flow cytometer (modified from 
http://regmed.musc.edu/flowcytometry/flowcytometry.html). 
 
 
One of the first applications of flow cytometry was the measurement of DNA content in 
cells. This analysis is based upon the ability to stain the cellular DNA in a stoichiometric 
manner (the amounts of stain are linearly to the amount of DNA inside the cell) (Rabinovitch 
(website)). In this study the fixed cells in samples were treated with the blue fluorescent dye 
Hoechst 33258 which binds to the minor groove of double-stranded DNA. The laser beam 
excites the fluorophores attached to the DNA in cells which causes them to emit light of a 
different wavelength than that of the laser. These signals are collected in the same direction 
as the side scatter, but pass through a series of filters to allow only certain wavelengths to 
reach the appropriate detectors.  
All G1 cells have the same DNA content.  Therefore, in theory the same fluorescence should 
therefore be observed from all cells in G1 phase (figure 2.6 A). This would be the case if the 
flow cytometer was perfect and if binding of the DNA- dye was exactly equal in all cells. In all 
real analysis, due to instrumental error in cytometers and biological variability in the binding 
of dye to DNA, the results from G1 cells is bell-shaped (Rabinovitch (website)) (figure 2.6 B) 
 
 
    «The fluidic system» 
«The optic system» 
«The electronic system» 
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Figure 2.6 Illustrates the results from a perfect flow cytometer with no errors in measurements (A) and the 
Gaussian broadening of the results that appear in all real analyses (B) (own figure). 
 
To avoid cell clusters, giving rise to duplicates that need to be gated out from in the results it 
is important that samples are properly vortexed before measurements in the flow cytometer 
(but not too hard as cells can be destroyed) (figure 2.7). Two cells in G1 phase clustered 
together produces a pulse height signal equal to a single cell in G2, but the flow cytometer 
can discriminate between the two, because clustered cells generate a signal with different 
pulse-with than single cells in G2.  
Apoptotic bodies have the same pulse-width as viable single cells, but because the DNA is 
fragmented (karyorrhexis), and the nucleus has been broken into several discrete 
nucleosomal units, the pulse-height registered is lower than in viable cells. Apoptotic index 
was therefore channeled to be events registered between G1 and 20% of the G1 peak.  As 
apoptosis progresses, the size of the fluorescent signal become progressively smaller and 
below 20% of G1, it will be gated out together with the background fluorescence. 
 
Figure 2.7 Picture to the left shows relatively few events of duplicates that need to be gated out from the 
results (the black dots); versus picture to the right showing relatively many events that needs to be gated out. 
Red events are gated out as background noise, while blue events are registered as apoptotic events.  
 A         B 
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2.4 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is an analysis that uses antibody-antigen interactions and associated color change to 
identify and quantify the concentration of a specific substance, most commonly a protein. It 
was first described by both Engvall and Perlmann, university of Stockholm, and Schuurs and 
van Wemen from the Netherlands independently in 1971 (Engvall and Perlmann 1971; Van 
Weemen and Schuurs 1971). 
In this study ELISA was used to quantify the concentration of cytokine interleukin -8 (IL -8) in 
supernatant from exposed and control cells. The primary antibody used, “capture”, binds to 
the plastic in the 96 well plate, and also the substance of interest (here, IL-8) when samples 
and standards are added to the wells (figure 2.8). Unbound materials are washed away, and 
the secondary antibody called “detection” is added to the wells and bind to the specific 
substance bound by the primary antibody. Unbound materials are washed away again and 
streptavidin-horseradish peroxidase (HRP) is added to the wells and bind to the secondary 
antibody. HRP has the ability to transform TMB (tetramethylbenzidine) from a colorless to a 
blue substrate. When TMB is added to the wells, blue color develops in proportion to the 
amount of the specific substance of interest present in the sample.  In a last step, stop 
solution containing sulfuric acid is added to wells. This stops color development and turn the 
color of the standards and samples to yellow. The absorbance is measured at 450 nm in a 
plate reader. Measurements of concentrations of antigen present in samples is done by 
preparing a standard curve with known concentrations of the antigen, and then compare the 
absorbance measured in samples with the absorbance from known concentrations. 
 
 
 
Figure 2.8 Illustrates the principle in a “sandwich” ELISA used in this study. The illustration is modified from a 
figure by R&D Systems (www.rndsystems.com). 
  
     «Capture» 
            «Detection» 
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3 Materials and methods 
Information about products and producers are listed in appendix 1. Recipes for all buffers 
and solutions used can be found in appendix 2.  
3.1 Cell culture 
The HT-29 APC cells were cultivated in 75 cm2 flasks (Sarstedt) with 25 ml of medium 
(McCoy's 5A Medium with L-glutamine, Lonza). The medium was supplemented with 1% of 
Penicillin-Streptomycin (10.000 U/ml) (Gibco), and 10% of fetal bovine serum (FBS) 
(Biochrom AG). Hygromycin B (0.6 mg/ml) (Hyclone Laboratories) was also added to the 
medium prior to use. These additives were included in all medium used in all experiments, 
and will hereafter be called “medium”.  Cells that loose the vector of resistance (pCEP4, 
Invitrogen) to hygromycin will thus die in the medium, and not be used in the experiments. 
All medium used with cells held 37°C. 
The cells were passaged when they were nearly 100 % confluent (about every third day). The 
old medium was removed carefully by suction, tilting the flask, to avoid damage to adherent 
cells. Dulbecco’s phosphate buffered saline (PBS) was added to the flask and removed 
carefully by suction twice to remove redundant medium (2 x 25 ml). Trypsin 
ethylenediaminetetraacetic acid (EDTA) (Lonza) was thereafter added to the flask (3 ml), and 
the flask was incubated at 37°C for 8 minutes to detach the adherent cells. Fresh medium 
(10 ml) was then added immediately, to stop the trypsination process. Incubating cells with 
too high a trypsin concentration for too long a time period will damage cell membranes and 
kill the cells. The automatic cell counter used before seeding out cells (Bio-Rad) also gave the 
proportion live cells. The proportion live cells were around 95% when counted, indicating 
that the trypsination process was not too hard for the cells. When the cells were counted, 10 
µl of cell suspension were mixed with 10 µl of trypan blue 0.4% (Lonza). Trypan blue is not 
able to stain viable cells, but will penetrate the membranes of dead cells giving them a 
distinctive blue color detected by the automatic cell counter. 1,25(OH)2D3 (Sigma-Aldrich) 
and ATRA (Sigma-Aldrich)  were dissolved in ethanol as recommended by the producers. 
Controls with corresponding concentrations of ethanol were therefore included in all 
replicates in all methods used in this study.  
All cell work was done in a ventilated cabinet (DanLaf) to maintain as sterile conditions as 
possible. The cells were kept in a humidified incubator (Seri-Cycle) at 37°C with 5% CO2.  All 
equipment that was brought into the cabinet or incubator while working with the cells was 
autoclaved and/or properly sprayed with Antibac 75% (Antibac AS) in advance. 
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3.2 Western blotting procedure 
Western blotting was performed to analyze if the levels of RXRα and VDR were influenced 
after exposure to different concentrations of 1,25(OH)2D3, ATRA and combinations of 
1,25(OH)2D3 and ATRA  
Three independent replicate experiments were performed. 
3.2.1 Culturing cells for western blotting: 
The cells were seeded in 10cm2 dishes from Sarstedt. To obtain the same amount of cells in 
each dish, the cells were counted in an automatic cell counter (Bio-Rad). 2 x 106 cells were 
seeded in each dish, and medium (McCoy’s) was added to a total of 10 ml. The dishes were 
kept in a CO2 incubator (Seri Cycle) at 37 °C were they were grown to near 80% confluence 
(about 48 hours), before they were exposed for 24 hours (see table 3.1) and then harvested. 
The treatments were added along the edge of the dish (where there were few or no cells), 
the dish was then immediately moved in a pattern similar to the number 8 to be sure that 
the treatments were equally distributed in the medium.  
Table 3.1 Treatments and concentrations cells were exposed to. 
Treatment: 
 
Concentration: 
Medium only (control)  
ATRA 10-7 M 
ATRA 10-6 M 
ATRA 10-5 M 
1,25(OH)2D3 10-9 M 
1,25(OH)2D3 10-7 M 
1,25(OH)2D3 10-5 M 
ATRA + 1,25(OH)2D3 10-6 M + 10-7 M 
ATRA + 1,25(OH)2D3 10-6 M + 10-5 M 
ATRA + 1,25(OH)2D3 10-5 M + 10-7 M 
ATRA + 1,25(OH)2D3 10-5 M + 10-5 M 
Ethanol (control) 10-9 M 
Ethanol (control) 10-7 M 
Ethanol (control) 10-6 M 
Ethanol (control) 10-5 M 
Ethanol (control) 10-6 M + 10-7 M 
Ethanol (control) 10-6 M + 10-5 M 
Ethanol (control) 10-5 M + 10-7 M 
Ethanol (control) 10-5 M + 10-5 M 
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3.2.2 Harvesting cells 
After 24 hours of exposure the cells were first observed in microscopy and then harvested. 
Medium was gently removed by suction. The dishes were tilted when medium was removed 
to avoid damaging the adherent cells. To remove redundant medium, Dulbecco’s PBS (10 ml) 
were added gently along the edge of the dishes two times, and removed carefully by suction 
along the wall (tilting the dishes again not to damage adherent cells). Any possibly remaining 
PBS were removed with tissue before the dishes were placed in small boxes upside down in 
a -20°C freezer for about 5 minutes and then placed in a -70°C freezer until further use. 
3.2.3 Preparation of cell lysate 
The dishes were immediately placed on ice when taken out of the freezer, and kept there 
the whole time. When samples had thawed, 200 µl of lysis buffer was added to each dish. A 
cell scraper (Sarstedt) was used to detach the adherent cells from the dishes, and the lysate 
was transferred to Eppendorf tubes. Based on the pilot experiment described in chapter 2.1, 
samples were sonicated 5 cycles of 30 seconds each. After sonication the lysates were 
centrifuged at 12.000 rpm for 10 minutes and the lysates were thereafter transferred to new 
Eppendorf tubes. The pellet was discarded. 
3.2.4 Determination of protein concentration 
To be sure that the same amount of protein was loaded in each well in the acrylamide gel, 
protein concentration was quantified in all lysates. The standards used to create a standard 
curve were made of bovine serum albumin (BSA) dissolved in 1 x lysis buffer. Three parallels 
of the standards and four parallels of the samples were added to a 96-well micro titer plate 
(Nunc). Solution A, B and S from DC Protein Assay (Bio-Rad) were added to both samples and 
standards. The plate was placed in the dark for 15 minutes as recommended in DC Protein 
Assay, before the absorbance at 750 nm were measured in a plate reader (BioTek). Data 
from the measurements were processed and analyzed using the software Gen5 (BioTek).  
3.2.5 Preparation of samples for loading into gels 
The protein concentration was diluted in 1 x lysis buffer to 1.25 μg/μl in all samples. In 
addition, 25 μl of glycerol and 50 μl of 5 x running buffer were added. The samples were 
thereafter put on a heating block at 95°C for 5 minutes.  
3.2.6 Preparation of polyacrylamide gels 
Because all proteins of interest were between 40 and 60 kDa, 10% polyacrylamide gels were 
used. Some of the gels were self-made and some of the gels were bought readymade (Bio-
Rad). The electrophoresis equipment was put on ice, and the electrophoresis buffer added 
held 4°C. The total amount of protein added to each well were 12.5 µl. 10 µl of the ladder 
“Precision Plus Protein™ Dual Xtra” (Bio-Rad)  were also added to the first well in all gels and 
served as a molecular weight marker that enables the determination of the protein size. 
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Both the ladder solution and samples were vortexed thoroughly before applied to the wells. 
The electrophoresis was run at 100 V (Power Pac, Bio-Rad) until all samples had formed a 
straight line in the gel. The power was then increased to 200 V.  
3.2.7 Transfer of proteins (blotting) 
During the blotting, the proteins were transferred from the gel to a nitrocellulose membrane 
(Whatman), by “wet transfer”. The transfer buffer held 4°C, and contained 20% methanol to 
increase binding of the proteins to the membrane. An ice block was placed in the blotting 
box to keep the temperature down together with a magnet stirrer to enhance circulation of 
cold fluid. The blotting was carried out for 1 hour at 70 V (Power Pac, Bio-Rad). 
3.2.8 Visualization of proteins in membranes 
To be sure that the proteins had been transferred evenly to the membrane, it was stained 
with Ponceau S. solution (Serva) for 1-2 minutes (figure 3.1).  
 
Figure 3.1 Showing a representative picture of a membrane were the transfer of proteins has been successful. 
 
3.2.9 Immunodetection 
The membranes were blocked for 60 minutes in wash buffer with 3% skim milk powder at 
room temperature with continous shaking. Subsequently, membranes were rinsed lightly in 
wash buffer, and then incubated with primary antibody overnight at 4°C (with continuous 
shaking). All antibodies were diluted in wash buffer with 3% skim milk powder. Dilution of all 
the antibodies used can be seen in Table 3.2.  
The following morning, the membranes were washed 3 x 5 minutes with wash buffer (the 
wash buffer was exchanged each round), and then incubated with secondary antibody for 1-
2 hours at room temperature with continous shaking. The membranes were thereafter 
washed in wash buffer 3 x 5 minutes again before they were incubated in a HRP substrate 
(Bio-Rad) for 3-5 minutes in the dark.  
The membranes were put between two sheets of plastic foil and the detection of the 
proteins of interest was done using Chemi-doc (Bio-Rad). The quantification of proteins was 
performed using the software Image Lab (Bio-Rad). 
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Table 3.2 Shows all types and dilutions of primary and secondary antibodies used.  
Primary antibody 
 
Producer Dilution 
 
Secondary antibody Dilution 
Anti-histone H1 Upstate (Millipore) 1:1000  Anti-mouse HRP 1:5000 
VDR antibody Santa Cruz 1:1000 Anti-rabbit HRP 1:5000 
RXRα antibody Santa Cruz 1:1000 Anti-rabbit HRP 1:5000 
Anti-β-actin Sigma-Aldrich 1:200 000 Anti-mouse HRP 1:5000 
 
 
3.3 Culturing the cells for fluorescence microscopy, flow cytometry and ELISA  
Cells were seeded in 6-well plates from Sarstedt. To obtain the same amount of cells in each 
well, the cells were counted in an automatic cell counter (Bio-Rad). 1 x 106 cells were seeded 
in each well, and medium (McCoy’s) was added to a total of 4 ml. The cells were kept in a 
CO2 incubator (Seri Cycle) at 37 °C were they were grown to near 80% confluence (about 48 
hours). The old medium was then removed by suction along the wall of the wells, tilting the 
plate, not to damage adherent cells. Cells were thereafter exposed for 24 hours (see table 
2.3) in a total of 1 ml medium (McCoy’s). The treatments were added along the edge of the 
wells (where there were few or no cells),  and the plates were immediately after moved in a 
pattern similar to number 8 to be sure that the treatments were equally distributed in the 
medium. 
 
Table 3.3 Treatments and concentrations cells were exposed to. 
Treatment: 
 
Concentration: 
Medium only (control)  
ATRA 10-7 M 
ATRA 10-6 M 
ATRA 10-5 M 
1,25(OH)2D3 10-9 M 
1,25(OH)2D3 10-7 M 
1,25(OH)2D3 10-5 M 
ATRA + 1,25(OH)2D3 10-6 M + 10-7 M 
ATRA + 1,25(OH)2D3 10-6 M + 10-5 M 
Ethanol (control) 10-9 M 
Ethanol (control) 10-7 M 
Ethanol (control) 10-6 M 
Ethanol (control) 10-5 M 
Ethanol (control) 10-6 M + 10-7 M 
Ethanol (control) 10-6 M + 10-5 M 
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3.3.1 Harvesting cells for fluorescence microscopy/flow cytometry and ELISA  
After 24 hours of exposure the cells were first observed in microscopy and then harvested. 
The supernatant was carefully collected in Eppendorf tubes, tilting the plates to avoid 
damaging the adherent cells. To remove redundant medium, Dulbecco’s PBS (1 ml) were 
added gently along the edge each well two times, and then removed carefully with suction 
along the wall (tilting the dishes again not to damage adherent cells). 300 µl of trypsin were 
added to each well and the plates were incubated for 10 minutes at 37°C. Stop solution (1 
ml/well ) containing 20% FBS were immediately after added to each well, to stop the 
trypsination process. The cell suspension was harvested and transferred to Eppendorf tubes. 
The wells were inspected in a light microscopy afterwards to ensure that all cells were 
collected in all wells.  
The supernatant was centrifuged for 10 minutes at 290 g. The supernatant was thereafter 
transferred to new Eppendorf tubes without disturbing the pellet, and immediately after put 
in a box  and placed in a -70°C freezer until further use (ELISA). The remaining pellet was 
mixed together with the pellet from the cell suspension in order to include all dead cells 
floating in the medium (see figure 3.2). 
 The cell suspension was centrifuged for 3 minutes at 700 g. Supernatant from the Eppendorf 
tube with cell suspension was discarded, and the pellet was mixed together with the pellet 
from the supernatant cells were exposed in ( as described above).The pellet was thereafter 
resuspended in 1 ml stop solution and split in two new Eppendorf tubes.   
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                                                                              Well 
 
 
 
                                   Medium from cell culture                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Illustration of the harvesting process of samples for fluorescence microscopy, flow cytometry and 
ELISA. 
 
 
 
 
  
Medium from cell 
culture 
Adherent cells (+ stop 
solution) 
      Centrifugation 
  Supernatant Pellet (dead 
cells floating in 
the medium) 
 Harvested cells    Supernatant 
Cells mixed together 
with 1 ml stop solution 
Used for cytokine 
measurement (ELISA) 
      Discarded 
500 µl used for flow cytometry 500 µl used for fluorescence microscopy 
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3.4 Fluorescence microscopy 
Fluorescence microscopy was carried out for two reasons: 
1. To analyze if the proportion of apoptotic cells were influenced when the cells were 
exposed to different concentrations of 1,25(OH)2D3, ATRA and combinations of 1,25(OH)2D3 
and ATRA. 
2. To be sure that the concentrations of treatments are not toxic to the cells, and thereby 
inducing necrosis. 
Four independent replicate experiments were performed. 
3.4.1 Preparation of samples for fluorescence microscopy 
10 µl of DNA staining color mix (Hoechst 33342/ Propidium Iodide) was added to each 
sample (500 µL cell suspension), and the samples were incubated in the dark for 30 minutes 
at room temperature. The samples were thereafter centrifuged for 10 minutes at 290 g, and 
the supernatant was discarded. The pellet was resuspended properly in 25 µl FBS. Three 
parallels of 2 µl cell suspension were added to microscope slides from all samples. The 
samples were put in a lightproof microscope slide box and placed in a refrigerator until 
further analysis. 
3.4.2 Analysis by fluorescence microscopy 
The microscopy was done using Nikon Eclipse E400 (Nikon Instruments, INC) at 100 x 
magnification, with oil. A minimum of 500 cells were counted on each slide, and they were 
categorized as either “viable”, “apoptotic” or “necrotic”, based on color and nuclear 
morphology. PI positive cells were counted as necrotic, while blue distinct condensed nuclei, 
segregated nuclei and apoptotic bodies were counted as apoptotic (PI negative). Non-
apoptotic PI negative cells were counted as viable cells. 
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3.5 Analysis by flow cytometry 
Flow cytometric analyses were carried out for two reasons: 
1. To investigate whether the proportion of apoptotic cells were influenced when the cells 
were exposed to 1,25(OH)2D3, ATRA and combinations of ATRA and 1,25(OH)2D3 
2. To see if the treatments mentioned above induced cell cycle alternations in HT-29 APC. 
Four independent replicate experiments were performed. 
3.5.1 Preparations for flow cytometry  
50 μl of 2% paraformaldehyde (Sigma-Aldrich) were added to each sample (500 µl cell 
suspension), and the Eppendorf tubes were vortexed gently to fixate the cells. The samples 
were thereafter put in a lightproof box and stored in a refrigerator at 4°C until further use. 
The day before the flow cytometry was performed; the samples were transferred to BD 
Falcon 5 ml PS tubes. 10 μl of DNA staining (Hoechst 33258/Sigma-Aldrich) was added to 
each sample, pipetting up and down properly in order to eliminate cell clusters. The samples 
were stored in a lightproof box in a refrigerator at 4°C until the next morning. 
3.5.2 Flow cytometry measurements 
The samples were vortexed properly before the tubes were put in the flow cytometer. The 
blue laser on the flow cytometer (BD biosciences) was used, while the detector Alexa Flour 
405 measured Hoechst 33258. G1 peak was adjusted if needed to 100 (x 1000) on the x-axis 
in all samples.  
The apoptotic index was channeled to be events registered between G1 peak, and 20% of the 
G1 peak (apoptotic events shown in blue in figure 2.7). Further analysis was done using BD 
FACSDiva™ software.  
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3.6 ELISA 
ELISA was performed to see if the levels of IL-8 secreted were influenced when the cells 
were exposed to different concentrations of 1,25(OH)2D3, ATRA and combinations of 
1,25(OH)2D3 and ATRA. 
Four independent replicate experiments were performed. 
3.6.1 Assay Procedure 
96 well plates (NUNC) were coated with 100 μl coating solution per well. Plates were 
covered and incubated overnight (12-18 hours) at 4 °C. The following morning, the wells 
were aspirated and washed one time with 400 μl wash buffer per well. Following wash, the 
plates were inverted and tapped on absorbent paper to remove excess liquid. The plates 
were thereafter blocked with 300 μl of assay buffer in each well for 1 hour at room 
temperature. The plates were aspirated, inverted and tapped on absorbent paper again to 
remove excess liquid before 100 μl of standards and samples were pipetted into designated 
wells. The samples were diluted 1:10 in assay buffer before they were added to the wells, 
because a pilot experiment was carried out in advance to see if it was necessary to dilute 
samples to keep the concentrations of IL-8 within the concentrations in the standard curve. 
Immediately after application of standards and samples, 50 μl of detection antibody solution 
were added to all wells. The plates were incubated for 2 hours at room temperature with 
continual shaking. Plates were thereafter aspirated and washed five times with wash buffer, 
inverted and tapped on absorbent paper. 100 μl of the working streptavidin HRP solution 
were added to each well, and the plates were incubated for 30 minutes at room 
temperature with continuous shaking. Plates were afterwards washed with wash buffer 5 
times, inverted and tapped on absorbent paper. TMB substrate (100 μl) was added to all 
wells, and the plates were incubated for 30 minutes at room temperature with continuous 
shaking. 100 μl of stop solution were immediately after added to each well, and the 
absorbance at 450 nm (reference absorbance: 650 nm) were measured in a plate reader 
(BioTek). Results were calculated using the software Gen5 (BioTek).  
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3.7 Statistical analysis 
In studies done using cell culture, the number of replicates is often very limited. In this study 
three individual experiments were performed in western blotting, and four individual 
experiments were carried out in fluorescence microscopy, flow cytometry and ELISA. 
Analysis of datasets using parametric tests as ANOVA assumes that the data are 
independent, normal distributed and that the variance between groups is uniform. When 
the data material is limited, it is often not possible to tell for sure if the data are normal 
distributed. In this study a normal distribution in results were assumed, and all data were 
tested for equal variance using Levene’s test (Levene 1960).  If there was significant 
heterogeneity in the variance, a log transformation of data was performed. If the variance 
remained unequal, analyses were conducted using Kruskal-Wallis non-parametric ANOVA 
with untransformed data. In cases where one-way ANOVA was significant, the result was 
followed up with Holm-Sidak post hoc test. 
The substances used to expose cells in this study were dissolved in rectified ethanol 
(Kemetyl). To exclude that the ethanol itself had any measurable effects on the cells, there 
were controls with ethanol equivalent to all concentrations the cells were exposed to in all 
replicates, in all methods used in this study. None of the concentrations of ethanol yielded 
significant effects on the cells. The results from the controls with ethanol will therefore not 
be graphed in results section, nor discussed further. 
All data were analyzed and graphically displayed using SigmaPlot 12.3 (Systat Software Inc, 
San Jose, CA 95110, USA).  
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4 Results 
4.1 Expression of VDR. 
There were no significant differences in the expression of VDR in cells exposed to 
1,25(OH)2D3 compared to the control cells (one-way ANOVA p=0.06) (figure 4.1 and 4.2).  
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Figure 4.1 Expression of VDR in cells exposed to 1,25(OH)2D3 compared to control cells (medium only). Bars 
representing average relative band intensity normalized to β-actin, while error bars represents SD (n=3). 
 
                                    
                                      
Figure 4.2 A representative blot showing VDR in cells exposed to 1,25(OH)2D3. Lanes 1-7 are: control (medium 
only), 10-9 M 1,25(OH)2D3  , 10
-9 M ethanol (control), 10-7 M 1,25(OH)2D3, 10
-7 M ethanol (control), 10-5 M 
1,25(OH)2D3, 10
-5 M ethanol (control). β-actin was used as a loading control. 
  
VDR (51 kDa) 
   Unknown protein (37 kDa) 
β-actin (42 kDa) 
   Unknown protein (80 kDa) 
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There were no significant differences in the in the level of VDR in cells exposed to 
combinations of 1,25(OH)2D3 and ATRA compared to control cells (one-way ANOVA p= 
1.0)(figure 4.3 and 4.4), and there were no significant differences in cells exposed to 
combinations of 1,25(OH)2D3 and ATRA compared to cells exposed to 1,25(OH)2D3 alone 
(one-way ANOVA p=0.6) 
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Figure 4.3 Expression of VDR in cells exposed to combinations of 1,25(OH)2D3 and ATRA compared to control 
cells (medium only). Bars representing average relative band intensity normalized to β-actin while error bars 
represents SD (n=3).  
                                      
                                    
Figure 4.4 A representative blot showing VDR. Lanes 1-9 are: control (medium only), 10
-7 M 1,25(OH)2D3 + 10
-6 
M ATRA  , 10
-7 M + 10-6 M ethanol (control), 10-7 M 1,25(OH)2D3 + 10
-5 M ATRA , 10-7 M + 10-5 M ethanol 
(control), 10-5 M 1,25(OH)2D3 + 10
-6 M ATRA,  10-5 M + 10-6 M ethanol (control),  105M 1,25(OH)2D3 + 10
-5,  M 
ATRA, 10-5 M + 10-5 M ethanol (control). β-actin was used as a loading control. 
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Unknown protein (37kDa) 
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 β-actin (42 kDa) 
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4.2 Expression of RXRα 
Analysis using one-way ANOVA indicated a significant decrease in the expression of RXRα in 
cells exposed to 10-9 M 1,25(OH)2D3 (Holm-Sidak p=0.007), and cells exposed to 10-7 M 
1,25(OH)2D3 (Holm-Sidak p=0.018) compared to the control cells. There were no observed 
significant differences in the cells exposed 10-5M 1,25(OH)2D3 compared to control cells 
(p=0.1)(figure 4.5 and 4.6).  
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Figure 4.5 Expression of RXRα in cells exposed to 1,25(OH)2D3 compared to control cells (medium only). Bars 
representing average relative band intensity normalized to β-actin, while error bars represents SD (n=3). The 
symbol * indicates a p-value below the significance level (p<0.05). Two asterisks indicate a p-value below 0.01. 
                                       
                                         
Figure 4.6 A representative blot showing RXRα in cells exposed to 1,25(OH)2D3. Lanes 1-7 are: control (medium 
only), 10-9 M 1,25(OH)2D3  , 10
-9 M ethanol (control), 10-7 M 1,25(OH)2D3, 10
-7 M ethanol (control), 10-5 M 
1,25(OH)2D3, 10
-5 M ethanol (control). β-actin was used as a loading control. 
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There were no significant differences in the expression of RXRα in cells exposed to ATRA 
compared to the control cells (one-way ANOVA p=0.3) (figure 4.7 and 4.8).  
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Figure 4.7 Expression of RXRα in cells exposed to ATRA compared to control cells (medium only). Bars 
representing average relative band intensity normalized to β-actin, while error bars represents SD (n=3). 
 
 
 
                                               
                                                 
Figure 4.8 A representative blot showing RXRα in cells exposed to ATRA. Lanes 1-7 are: control (medium only), 
10-7 M ATRA  , 10
-7 M ethanol (control), 10-6 M ATRA, 10-6 M ethanol (control), 10-5 M ATRA, 10-5 M ethanol 
(control). β-actin was used as a loading control. 
 
  
   β-actin (42 
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There were no significant differences in the cells exposed to combinations of 1,25(OH)2D3 
and ATRA, and control cells (one-way ANOVA p=0.8 .)(figure 4.9 and 4.10). There were not 
any significant differences observed in cells exposed to combinations of 1,25(OH)2D3 and 
ATRA compared to cells exposed to 1,25(OH)2D3 alone (one-way ANOVA p=0.5), or cells 
exposed to  1,25(OH)2D3 and ATRA compared to cells exposed to ATRA alone (one-way 
ANOVA p=0.7). 
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Figure 4.9 Expression of RXRα in cells exposed to combinations of 1,25(OH)2D3 and ATRA compared to control 
cells (medium only). Bars representing average relative band intensity normalized to β-actin while error bars 
represents SD (n=3). 
                                           
                                       
Figure 4.10 A representative blot showing RXRα. Lanes 1-9 are: control (medium only), 10-7 M 1,25(OH)2D3 + 10-6 
M ATRA  , 10
-7 M + 10-6 M ethanol (control), 10-7 M 1,25(OH)2D3 + 10
-5 M ATRA , 10-7 M + 10-5 M ethanol 
(control), 10-5 M 1,25(OH)2D3 + 10
-6 M ATRA,  10-5 M + 10-6 M ethanol (control),  105M 1,25(OH)2D3 + 10
-5,  M 
ATRA, 10-5 M + 10-5 M ethanol (control). β-actin was used as a loading control. 
Unknown proteins (70/90 kDa) 
RXRα (52 kDa) 
   Unknown protein (40 kDa) 
β-actin (42 kDa) 
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4.3 Necrosis 
There were no significant differences in cells exposed to 1,25(OH)2D3, compared to the 
control cells (one-way ANOVA p=0.5), cells exposed to ATRA compared to control cells (one-
way ANOVA p=0.6), or cells exposed to combinations of  1,25(OH)2D3 and ATRA compared to 
the control cells (one-way ANOVA p=0.6)(figure 4.11). Furthermore, there were no 
significant differences observed between cells exposed to 1,25(OH)2D3 alone compared to 
cells exposed to combinations of 1,25(OH)2D3 and ATRA (Kruskal-Wallis  one-way ANOVA on 
ranks p=0.5), or in cells exposed to ATRA alone compared to cells exposed to cells exposed 
to combinations of 1,25(OH)2D3 and ATRA (one-way ANOVA p=0.2). 
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Figure 4.11 Necrosis in cells exposed to 1,25(OH)2D3, ATRA, and  to combinations of 1,25(OH)2D3 and ATRA 
compared to control cells ( medium only).The boxplot show first quartile, median and third quartile. Vertical 
point plot show each data point (n=4). 
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4.4 Apoptosis 
4.4.1 Apoptosis by fluorescence microscopy 
There were no observed significant differences in cells exposed to 1,25(OH)2D3, compared to 
the control cells (one-way ANOVA p=0.3), cells exposed to ATRA compared to control cells 
(one-way ANOVA p=1.0), or cells exposed to combinations of  1,25(OH)2D3 and ATRA 
compared to the control cells (one-way ANOVA p=0.3)(figure 4.12). Moreover, were no 
significant differences observed between cells exposed to 1,25(OH)2D3 alone compared to 
cells exposed to combinations of 1,25(OH)2D3 and ATRA (one-way ANOVA p=0.08), or in cells 
exposed to ATRA alone compared to cells exposed to cells exposed to combinations of 
1,25(OH)2D3 and ATRA (one-way ANOVA p=0.8). 
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Figure 4.12 Apoptosis in cells exposed to 1,25(OH)2D3, ATRA, and  to combinations of 1,25(OH)2D3 and ATRA 
compared to control cells ( medium only).The boxplot show first quartile, median and third quartile. Vertical 
point plot show each data point (n=4). 
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4.4.2 Apoptosis by flow cytometry 
There were no significant differences in cells exposed to 1,25(OH)2D3, compared to the 
control cells (one-way ANOVA p=0.3), cells exposed to ATRA compared to control cells (one-
way ANOVA p=0.7), or cells exposed to combinations of  1,25(OH)2D3 and ATRA compared to 
the control cells (one-way ANOVA p=0.6)(figure 4.13). There were neither any significant 
differences observed between cells exposed to 1,25(OH)2D3 alone compared to cells 
exposed to combinations of 1,25(OH)2D3 and ATRA (one-way ANOVA on log transformed 
data p=0.08), or in cells exposed to ATRA alone compared to cells exposed to cells exposed 
to combinations of 1,25(OH)2D3 and ATRA (one-way ANOVA p=0.2). 
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Figure 4.13 Apoptosis in cells exposed to 1,25(OH)2D3, ATRA, and  to combinations of 1,25(OH)2D3 and ATRA 
compared to control cells (medium only).The boxplot show first quartile, median and third quartile. Vertical 
point plot show each data point (n=4). 
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4.5 Cell cycle analysis 
There were no significant differences in the cell cycle in any of the treated cells (Figure 4.14). 
Summary of p-values using one-way ANOVA can be seen in Table 4.1. 
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Figure 4.14 Cell cycle analysis from cells exposed to 1,25(OH)2D3, ATRA, and  to combinations of 1,25(OH)2D3 
and ATRA compared to control cells (medium only). Bars represents average proportion of cells in population 
(n=4). 
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Table 4.1 Overview over the statistical results using one-way ANOVA to observe differences in cell cycle 
between control cells and treated cells. 
Cell 
phase 
 
Treatment P-value 
G1 
 
Control versus 1,25(OH)2D3 0.7 
G1 
 
Control versus ATRA 1.0 
G1 Control versus combinations of 1,25(OH)2D3 and 
ATRA 
1.0 
G1 1,25(OH)2D3 versus combinations of 1,25(OH)2D3 
and ATRA 
0.7 
G1 
 
ATRA versus combinations of 1,25(OH)2D3 and ATRA 0.9 
S 
 
Control versus 1,25(OH)2D3 1.0 
S 
 
Control versus ATRA 0.8 
S 
 
Control versus combinations of 1,25(OH)2D3 and 
ATRA 
0.8 
S 
 
1,25(OH)2D3 versus combinations of 1,25(OH)2D3 
and ATRA 
0.8 
S 
 
ATRA versus combinations of 1,25(OH)2D3 and ATRA 0.8 
G2 
 
Control versus 1,25(OH)2D3 1.0 
G2 
 
Control versus ATRA 1.0 
G2 
 
Control versus combinations of 1,25(OH)2D3 and 
ATRA 
1.0 
G2 
 
1,25(OH)2D3 versus combinations of 1,25(OH)2D3 
and ATRA 
1.0 
G2 
 
ATRA versus combinations of 1,25(OH)2D3 and ATRA 1.0 
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4.6 Release of IL -8 
With respect to IL -8, there were no significant differences in cells exposed to 1,25(OH)2D3, 
compared to the control cells (one-way ANOVA p=0.5), cells exposed to ATRA compared to 
control cells (one-way ANOVA p=0.3), or cells exposed to combinations of  1,25(OH)2D3 and 
ATRA compared to the control cells (one-way ANOVA p=0.3)(figure 4.15). There were neither 
any significant differences observed between cells exposed to 1,25(OH)2D3 alone compared 
to cells exposed to combinations of 1,25(OH)2D3 and ATRA (one-way ANOVA p=0.6), or in 
cells exposed to ATRA alone compared to cells exposed to cells exposed to combinations of 
1,25(OH)2D3 and ATRA (one-way ANOVA p=0.6). 
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Figure 4.15 Release of IL -8 in cells exposed to 1,25(OH)2D3, ATRA, and  to combinations of 1,25(OH)2D3 and 
ATRA compared to control cells (medium only).The boxplot show first quartile, median and third quartile. 
Vertical point plot show each data point (n=4). 
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5 Discussion 
This study primarily aimed to clarify whether vitamin A may have an antagonistic effect on 
vitamin D by competing for the same nuclear receptor by analyzing levels of VDR and RXRα 
in HT-29 APC cells. Subordinate objectives were to clarify whether the treatments would 
have an effect on necrosis, apoptosis, cell cycle or release of IL -8.   
The experimental data from this study did not show significant changes in the levels of VDR 
with increasing dose of 1,25(OH)2D3. There was however a tendency to increased level of 
VDR in cells exposed to the highest concentration (10-5 M). There were only three replicate 
experiments. Two of the replicates clearly resulted in higher level of VDR, while the third 
resulted in distinct lower level of VDR. It is thus a possibility that additional replicate 
experiments could have resulted in an overall significant result. There were however no 
tendency to increase in VDR in cells exposed to combinations of 1,25(OH)2D3 and ATRA. Up-
regulation of the VDR and the corresponding mRNA by 1,25(OH)2D3 has previously been 
shown in bone cell models (Pan and Price 1987), and such changes seem to be time and dose 
dependent (Mahonen et al. 1990). Costa et al. reports that such effect also is seen in human 
skin fibroblast and human mammary cancer cells, and that time needed to achieve maximal 
increase in receptor level is 16-20 hours (Costa et al. 1985). Furthermore, Zhao and Feldman 
(1993) studied regulation of VDR abundance and responsiveness in HT-29 cells. By use of 3H 
(tritium) ligand binding experiments, they found that HT-29 cells exposed to 10-8 M 
1,25(OH)2D3  exhibited up-regulation of VDR to approximately 150% at 24 hours (Zhao and 
Feldman 1993). The results are in contrast to results reported by Kane et al.(1996). Kane et 
al. exposed HT-29 and Caco-2 (another human colorectal cancer cell line) to 10-10 M, 10-9 M, 
10-8 M and 10-7 M 1,25(OH)2D3. They found that VDR was significantly increased in Caco-2 
cells, but no effect was seen in in HT-29 by western blotting. Furthermore, they did not find 
any response on VDR levels in either cell line exposed to 9-cis-retinoic acid.  This is 
interesting, because no effect was seen during our study in cells exposed to combinations of 
1,25(OH)2D3  and all-trans retinoic acid. Kane et al suggest that nuclear receptor signaling is 
determined by a complex equilibrium within the nucleus including availability of ligand, the 
stoichiometry of heterodimer partners, the individual target gene activated, or other cell 
specific proteins (Kane et al. 1996). VDR levels are also found to be increased by 1,25(OH)2D3  
in vivo in rat kidney and intestine in previous studies. The effect seen in kidney is reported to 
be clear-cut and can be seen after 1 day, and persists for at least 5 days (Costa and Feldman 
1986). The results in the intestine are less substantial (Gensure et al. 1998). The mechanism 
used by 1,25(OH)2D3  to regulate VDR is not known, but is demonstrated to be at least 
partially by activation of gene expression (Mangelsdorf et al. 1987). Little is known about 
transcriptional regulation of this pathway, but in the renal system increase of the mRNA 
seems to occur by mRNA stabilization (Enomoto et al. 1992). Increase in VDR half-life has 
also been documented (Wiese et al. 1992).  
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The level of RXRα was significantly decreased in cells exposed to 10-9 M and 10-7 M 
1,25(OH)2D3  in the current study. Surprisingly, the level of RXRα was lowest in cells exposed 
to the lowest concentrations, while cells exposed to the highest concentration (10-5 M) were 
not significantly altered relative to unexposed control cells. No effects on RXRα was seen in 
cells exposed to ATRA alone, or in cells exposed to combinations of 1,25(OH)2D3  and ATRA. 
RXR expression can be regulated by transcriptional or posttranscriptional mechanisms. In a 
study with HT-29 and Caco-2 cells, the relative expression of RXRα mRNA was not altered 
after treatment with 1,25(OH)2D3 or  9-cis-retinoic acid for 6 and 24 hours (Kane et al. 1996). 
Findings from three different osteosarcoma cell lines indicated a posttranscriptional 
regulatory mechanism as the cell lines contained similar amounts of RXR mRNA, but various 
amounts of RXR protein (Williams et al. 1994). Protease degradation have been 
demonstrated in human keratinocytes for both RXR (Boudjelal et al. 2000) and VDR (Li et al. 
1999). Furthermore, increased protease activity in cancer cells have been correlated with 
malignancy in human leukemic cells (Kumatori et al. 1990). Prufer et al. (2002) suggests that 
RXR degradation can be regulated in cancer cells because they found that degradation of 
RXRα is abnormal and accelerated in a rat osteosarcoma cell line (ROS cells) compared with 
noncancerous cells from the kidney of an African green monkey (CV-1 cells), by use of 
western blotting. In addition, they found that both protease inhibitors and the introduction 
of recombinant RXR restored the responsiveness of ROS cell with regards to growth 
inhibitory effects of 1,25(OH)2D3  and 9-cis-retinoic acid (Prufer et al. 2002).   
Taken together, it seems that with regards to the expression of VDR and RXRα there are 
differences between different tissues, but also within cell lines from the same type of tissue. 
The results from the current study indicate that HT-29 APC cells probably have the ability to 
regulate the expression of VDR and RXRα receptor, and that this may depend on the amount 
of ligand present. However, an antagonistic effect of vitamin A on vitamin D with respect to 
competition for RXR can neither be confirmed nor excluded. This is based upon the results 
showing that the levels of RXRα was not altered in cells exposed to the combinations of 
1,25(OH)2D3 and ATRA when compared to control cells or to cells exposed to 1,25(OH)2D3 or 
ATRA separately. The observation that levels of RXRα were not increased above control level 
at any exposure may suggest a possible upward limitation for the expression of RXRα in    
HT-29 APC cells. 
HT-29 APC cells were exposed to 1,25(OH)2D3, ATRA, and combinations of the two 
mentioned including ethanol used as a vehicle (table 3.1 and 3.3).  No effect on necrosis was 
observed in cells in either treatment group. This was important to examine, to rule out that 
any possible significant results were caused by toxic effects due to too high concentrations 
of the treatments. Also, different cell lines have different tolerance levels to substances. 
ATRA is regularly applied to a variety of cell cultures at 10-9 M -10-5 M (Arsenou et al. 2005; 
Plantier et al. 2008) but no data were found on HT-29 cells and the use of 10-5 M ATRA. 
1,25(OH)2D3 is routinely used in cell cultures at 10-12 -10 -6 M , including HT-29 (Bessler and 
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Djaldetti 2012; Kane et al. 1996). Interestingly, no toxic effect was seen in HT-29 APC cells 
exposed to 10-5 M 1,25(OH)2D3  or 10-5 M ATRA during the present study. 
Apoptotic cell death was investigated in HT-29 APC cells to find out if the treatment would 
affect the proportion of apoptotic cells. Apoptosis was analyzed using both fluorescence 
microscopy and flow cytometry. No differences in the proportion of apoptotic cell were seen 
in either treatment group. Counting cells using fluorescence microscopy is relatively time 
consuming, and early apoptotic stages, with little nuclear condensation and fragmentation 
may prove difficult to detect to the untrained eye. Compared with fluorescence microscopy, 
the use of a flow cytometer to measure apoptosis is less time consuming, additionally, it is 
possible to investigate a larger amount of cells in the samples than with manual counting. 
However, late apoptotic stages where the nucleus has split into for example 4 apoptotic 
bodies will be counted as 4 events in the flow cytometer, even though they origin from 1 
cell. Results from flow cytometry is therefore termed “apoptotic index”, while results from 
fluorescence microscopy is termed “apoptotic cells (%)”. ATRA treatment with 2 x 10-9 M has 
previously been found to induce apoptosis in HCT-15 human colorectal cancer cell line (Miao 
et al. 2011) and 1,25(OH)2D3  has been found to induce apoptosis in several types of cancer 
cells, including colorectal cancer cell lines (Ylikomi et al. 2002). The HT-29 APC cell line used 
in the current study expresses a mutant p53 protein, which probably makes the protein non-
functional. The tumor suppressor gene p53 regulates various cellular events, as the 
induction of apoptosis and cell cycle arrest (Mihara et al. 2003). This might explain the lack 
of response to induction of apoptosis in HT-29 APC during this study.   
Cell cycle analysis of HT-29 APC cells were conducted to evaluate whether there were 
differences in the cell cycle in exposed and control cells. No effects were seen in either 
treatment group. Gibson et al.(1998) exposed cells that were isolated from newborn human 
foreskins (NHK cells), and the human squamous cell carcinoma cell line SCC4 for 10-10, 10-9 
and 10-8 M 1,25(OH)2D3, 10-8 and 10-6 M ATRA, and in addition combinations of the two for 6 
days. The NHK cells exhibited maximal growth inhibition achieved by 10-8 M 1,25(OH)2D3  
alone and 10-6 M ATRA alone. When 1,25(OH)2D3  and ATRA were added to NHK cells 
together, their antiproliferative actions  were partially reversed. Furthermore, the cancer cell 
line (SCC4) was unresponsive to 1,25(OH)2D3  treatment with regards to antiproliferative 
effects, and effects were only seen in the highest concentration of ATRA (Gibson et al. 1998). 
Prufer et al. (2002) reports that ROS cells do not respond to 1,25(OH)2D3  treatment with 
respect to growth inhibition unless treated with protease inhibitors or recombinant RXR as 
mentioned earlier. Kane et al. (1996)  found that treatment of HT-29 cells with 1,25(OH)2D3 
for 72 hours resulted in a significant antiproliferative effect at concentrations of 10-11 M. HT-
29 treated with 10-13 - 10-7 M 1,25(OH)2D3 and 10-10-10-7 M 9-cis-RA resulted in inhibition of 
the antiproliferative effects of 1,25(OH)2D3 . Cotreatment with 10-7 M 9-cis-RA blocked the 
antiproliferate actions of 1,25(OH)2D3  completely.  Additionally they reported that Caco-2 
cells exposed to 10-10-10-7 M 1,25(OH)2D3, or 9-cis RA  alone yielded significant 
antiproliferative effects. However, the antagonistic effect seen in HT-29 with combined 
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treatments of 1,25(OH)2D3 and ATRA was not seen in Caco-2 cells. Because of the differences 
in responses to 1,25(OH)2D3  and 9-cis retinoic acid in the human colorectal cancer cell lines  
HT-29 and Caco-2,  Kane et al. concludes that the use of HT-29 and Caco-2 cells as 
representative models of colon cancer is too simplistic (Kane et al. 1996). HT-29 APC cells 
used in the current study were exposed to treatments in 24 hours without any effect. This 
was perhaps too short a time period to observe a response in the cell cycle, as Kane et al. 
exposed HT-29 cells for 72 hours.   
By use of ELISA, the proportion of secreted IL -8 secreted in the medium was quantified. No 
differences in the amount of IL -8 were observed in any treatment group. Ding el al. (2013) 
found that human adipocytes that were pretreated with 10- 8 M 1,25(OH)2D3  for 48 hours, 
and subsequent exposed to macrophage-conditioned medium (MC medium) to induce 
inflammation (24 hours), exhibited a significant reduction in MC medium-elicited release of 
IL -8 (Ding et al. 2013).  1,25(OH)2D3  have also been reported to inhibit the production of IL -
8 by peripheral blood mononuclear cells in diabetic patients (Giulietti et al. 2007). ATRA on 
the other hand is shown to stimulate the production of IL -8. Dai et al. (2004) reports that 
human keratinocytes exposed for 10-8-10-5 M ATRA for 36 hours exhibited a concentration –
dependent up-regulation with regards to release of IL-8 into the culture medium. There 
were significant higher levels from in cells exposed to 10-7, 10-6 and 10-5 M (Dai et al. 2004). 
Nevertheless, the lack of response with regards to IL -8 in HT-29 APC cells during the current 
study may be explained by too short exposure period or cell specific properties. In addition, 
a substance that induces inflammation in the cell culture may be needed to observe the anti-
inflammatory effect of 1,25(OH)2D3  with regards to the amount of IL-8 released from 
cultured cells.  
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6 Conclusions 
The levels of VDR and RXRα in HT-29 APC cells exposed to 1,25(OH)2D3, ATRA and 
combinations of 1,25(OH)2D3  and ATRA were investigated. The results indicate that HT-29 
APC cells may have the ability to regulate the levels of VDR and RXRα. However, the levels of 
RXRα was not altered in cells exposed to combinations of 1,25(OH)2D3  and ATRA when 
compared to control cells or to cells exposed to 1,25(OH)2D3 or ATRA alone. These results 
may also indicate a possible upwards limitation for the level of RXRα expression. An 
antagonistic effect of vitamin A in vitamin D with respect to competition for RXR in HT-29 
APC cells can therefore neither be confirmed nor excluded. 
The proportions of necrotic cells treated with 1,25(OH)2D3,  ATRA and combinations of  
1,25(OH)2D3  and ATRA were examined. There were no indications that any of the treatments 
used caused an increase in the proportion in necrotic HT-29 APC cells. 
The influence of 1,25(OH)2D3,  ATRA and combinations of  1,25(OH)2D3  and ATRA with 
respect to apoptosis were analyzed by both fluorescence microscopy and flow cytometry. 
No differences in the proportion of apoptotic cells were observed in either treatment group 
in HT-29 APC cells. 
The effects of 1,25(OH)2D3, ATRA and combinations of  1,25(OH)2D3  and ATRA were 
examined with regards to cell cycle alternations in HT-29 APC cells. No effects on the cell 
cycle were seen in either treatment group. 
Release of the inflammatory marker IL -8 by HT-29 APC cells exposed to 1,25(OH)2D3, ATRA 
and combinations of  1,25(OH)2D3  and ATRA were quantified. There were no significant 
differences in the level of IL -8 released from HT-29 APC cells in any of the treatment groups.   
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8 Appendixes 
8.1 Appendix 1: products and producers 
Cell culture 
Chemicals: 
McCoy's 5A Medium with L-glutamine Lonza bioscience, 8830 Biggs Ford Road, 
Walkersville, USA 
Pen Strep (10.000 U/ml) Gibco, Life Technologies, Grand Island, NY 
14072, USA 
FBS Superior Biochrom AG, Leonorenstr. 2-6, 12247 
Berlin, DE 
Hygromycin B solution Hyclone laboratories, logan, 84321 Utah,  
USA 
Tryphan Blue 0.4 % Lonza bioscience, 8830 Biggs Ford Road, 
Walkersville, USA 
Trypsin EDTA Lonza bioscience, 8830 Biggs Ford Road, 
Walkersville, USA 
Sodium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Sodium phosphate dibasic Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium phosphate monobasic Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
1α,25-dihydroxyvitamin D₃, catalog nr. 
D1530 
Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
all trans-RETINOIC ACID, Sigma Prod. No. R 
2625 
Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Antibac 75 % Antibac AS, Hagaløkkveien 13, 1383 Asker, 
NO 
 
Lab equipment: 
Cell culture flasks 75cm2 Sarstedt AG & Co, Rommelsdorfer st., 51582 
Numbrecht, DE 
 
Instruments: 
TC10™ Automated Cell Counter Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Seri Cycle CO2 incubator Thermo Fisher scientific, Waltham,  USA 
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Western blotting: 
Chemicals: 
Acrylamide/Bis Solution (30 %) Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
TEMED  Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Ammonium Persulfate Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Natrium dodecyl sulfate ( SDS) Fluka, Sigma-Aldrich, 3050 Spruce St., St. 
Louis, MO 63103, USA 
β-mercaptoethanol Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
1 % bromophenol blue Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Glycerol Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Glycine Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Leupeptin (L-2884) Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Aprotinin (A-1153) Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Pepstatin A Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
PMFS Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Trizma-hydrochloride Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
NaCl  Merck, Whitehouse Station, NJ 08889-0100,  
USA 
EDTA Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
EGTA Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Sodium pyrophosphate Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Natrium Orthovanadate Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Sodium Fluoride Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Triton X-100 Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Skim milk powder Fluka, Sigma-Aldrich, 3050 Spruce St., St. 
Louis, MO 63103, USA 
Trizma-base Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
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63103, USA 
Tween 20 Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Potassium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Sodium phosphate dibasic Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium phosphate monobasic Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
HeLa nuclear extract: sc-2120 (positive 
control)  
Santa Cruz Biotechnology, Dallas, Texas 
75220, USA 
Rectified ethanol Kemetyl Norge AS, Delitoppen 3, 1541 
Vestby, NO 
DC protein assay Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Sterile water B. Braun, Carl-Braun-St. 1,  34212 
Melsungen, DE 
Mini-PROTEAN TGX precast gels 10% Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Ponceau S solution for electrophoresis (0.2 
%) 
SERVA GmbH, Carl-Benz-Str. 7, 69115 
Heidelberg, DE 
SuperSignal WestDura Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Precision Plus Protein™ Dual Xtra Standard Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
 
Antibodies: 
VDR Antibody (C-20): sc-1008 Santa Cruz Biotechnology, Dallas, Texas 
75220, USA 
RXRα Antibody (D-20): sc-553 Santa Cruz Biotechnology, Dallas, Texas 
75220, USA 
Monoclonal Anti-β-Actin antibody produced 
in mouse, clone AC-74 
Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Anti-Histone H1 antibody Upstate (Millipore), 290 Concord Road, 
Billerica, MA 01821, USA 
Polyclonal Goat Anti-Rabbit 
Immunoglobulins/HRP 
Dako Denmark A/S, Productionsvej 42, 2600 
Glostrup,  DK 
Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/HRP 
Dako Denmark A/S, Productionsvej 42, 2600 
Glostrup,  DK 
 
Lab equipment: 
PROTRAN nitrocellulose Transfer membrane Whatman GmbH, Hahnestr. 3, 37586 Dassel,  
DE 
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10 cm dishes  Sarstedt AG & Co, Rommelsdorfer st., 51582 
Numbrecht, DE 
Cell scraper Sarstedt AG & Co, Rommelsdorfer st., 51582 
Numbrecht, DE 
 
Instruments: 
Chemi-Doc Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Bioruptor plus Diagenode, Rue Bois Saint-Jean 3, 4102 
Seraing, BE 
EL 808 Microplate reader BioTek, 13500 Linden Ave N, Seattle, WA 
98133, USA 
Power Pac 300  Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
 
Software: 
Image Lab Bio-Rad Laboratories, Hemel Hempstead, 
Hertz HP2 7DX, UK 
Gen5 BioTek, 13500 Linden Ave N, Seattle, WA 
98133, USA 
 
ELISA: 
Chemicals: 
di-Sodium hydrogen phosphate 
dodecahydrate (HNa2O4P · 12H2O) cat. # 
A3906  
AppliChem GmbH, Ottoweg 4, 64291 
Darmstadt, DE 
Sodium chloride pure Ph. Eur. Cat. # A1371 AppliChem GmbH, Ottoweg 4, 64291 
Darmstadt, DE 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4 * H2O) Cat. # 1.06346 
Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Tween 20 Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Potassium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Sodium phosphate dibasic Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium phosphate monobasic Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Sodium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
FBS Superior Biochrom GmbH, Leonorenstrasse 2-6, 
61 
 
12247 Berlin,  DE 
Assay Buffer, Cat. # DS98200 Invitrogen Corporation, Carlsbad, CA 92008, 
USA 
Coating Buffer, cat # CB07100 Invitrogen Corporation, Carlsbad, CA 92008, 
USA 
TMB,Cat. # SB01 Invitrogen Corporation, Carlsbad, CA 92008, 
USA 
H2SO4 Merck, Whitehouse Station, NJ 08889-0100,  
USA 
 
KIT: 
Human IL-8 CytoSet Invitrogen Corporation, Carlsbad, CA 92008, 
USA 
 
Lab equipment 
96 well NUNC MaxiSorp microplates Nunc A/S, Kamstupvej 90, 4000 Roskilde, DK 
 
6 well plates Sarstedt AG & Co, Rommelsdorfer st., 51582 
Numbrecht, DE 
 
Instruments: 
405 LS Microplate washer BioTek, 13500 Linden Ave N, Seattle, WA 
98133, USA 
EL 808 Microplate reader BioTek, 13500 Linden Ave N, Seattle, WA 
98133, USA 
 
Software: 
Gen5 BioTek, 13500 Linden Ave N, Seattle, WA 
98133, USA 
 
Flow cytometry: 
Chemicals: 
FBS Superior Biochrom GmbH, Leonorenstrasse 2-6, 
12247 Berlin,  DE 
Sodium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium chloride Merck, Whitehouse Station, NJ 08889-0100,   
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Sodium phosphate dibasic Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium phosphate monobasic Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Hoechst 33258 Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Triton X-100  Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Paraformaldehyde Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
 
Lab equipment 
BD Falcon 5 ml poly styrene tubes BD Biosciences, 2350 Qume Drive,  San Jose, 
CA 95131, USA 
 
Instruments: 
BD LSR II BD Biosciences, 2350 Qume Drive,  San Jose, 
CA 95131, USA 
 
Software: 
BD FACSDiva™ software BD Biosciences, 2350 Qume Drive,  San Jose, 
CA 95131, USA 
 
Fluorescence microscopy 
Chemicals: 
FBS Superior Biochrom GmbH, Leonorenstrasse 2-6, 
12247 Berlin,  DE 
Sodium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium chloride Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Sodium phosphate dibasic Merck, Whitehouse Station, NJ 08889-0100,  
USA 
Potassium phosphate monobasic Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA 
Hoechst 33342 Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 
63103, USA  
Propidium Iodide Invitrogen Corporation, Carlsbad, CA 92008, 
USA 
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Instruments: 
Nikon Eclipse E400 Nikon Instruments INC, Melville, NY 11747,  
USA 
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8.2 Appendix 2: buffers and solutions 
Western Blotting: 
 
Wash buffer 10 mM Tris-HCL buffer 12 g 
0.15 mM NaCl 80 g 
0.1 % v.v. Tween 20 10 ml 
Distilled water Fill up to a total of 1000 ml 
Adjust pH if necessary to 7.6 
 
5 x Lysis buffer 0.5 mM Tris-HCl pH 7.5 6 ml 
NaCl 1.32 g 
0.5 M EDTA 300 µl 
1 mM EGTA 57 mg 
2.4 mM Sodium 
pyrophosphate 
167 mg 
1 mM Sodium orthovandate 27.6 mg 
Triton X-100 1500 µl 
0.5 M Sodium Fluoride 300 µl 
Distilled water 30 ml 
 
1 x Lysis buffer 5 x  Lysis buffer 0.5 ml 
10 mg/ml Leupeptin 2.5 µl 
0.1 M PMFS 25 µl 
10 mg/ml Pepstatin A 25 µl 
10 mg/ml Apoprotein 2.5 µl 
Distilled water 1968 µl 
 
Leupeptin 10 mg/ml Leupeptin (L-2884) 5 mg 
Distilled water 500 µl 
 
Aprotinin 10 mg/ml Apoprotein (A-1153) 10 mg 
Distilled water 1 ml 
 
Pepstatin A 10 mg/ml Pepstatin A (P-5318) 5 mg 
DMSO 5.0 ml 
 
APS APS 1 g 
Distilled water 10 ml 
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5 x Running buffer 0.5 mM Tris-HCl, pH 6.8 12.48 ml 
SDS 2 g 
β-mercaptoethanol 5 ml 
1 % bromophenol blue 1 ml 
Distilled water Fill up to a total of 20 ml 
 
0.5 M Tris-HCl, pH 6.8 Trizma-HCl 17.5 g 
Trizma-base 1.7 g 
Distilled water Fill up to a total of 250 ml 
Adjust pH to 6.8 if necessary 
 
1.5 M Tris-HCl, pH 8.8 Trizma-HCl 9.2 g 
Trizma-base 38.5 g 
Distilled water Fill up to a total of 250 ml 
Adjust pH to 8.8 If necessary 
 
Dulbecco’s PBS KCl 0.2 g 
KH2PO4 0.2 g 
NaCl 8 g 
Na2HPO4 1.15 g 
 
10 x Transfer buffer Trizma-base 30 g 
Glycine 144 g 
Distilled water Fill up to a total of 1000 ml 
 
1 x Transfer buffer 10 x transfer buffer 100 ml 
Methanol 200 ml 
Distilled water 700 ml 
 
10 x Electrophoresis buffer Trizma-base 30 g 
Glycine 144 g 
SDS 10 g 
Distilled water Fill up to a total of 1000 ml 
 
1 x Electrophoresis buffer 10 x Electrophoresis buffer 100 ml 
Distilled water 900 ml 
 
3 % Skim milk solution Skim milk powder 15 g 
Western wash buffer 500 ml 
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“homemade” acrylamide 
gels (10%) 
30 % acrylamide mix 3.3 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10 % SDS 0.1 ml 
10 % Ammonium persulfate 0.1 ml 
TEMED 0.004 ml 
Distilled water 4.0 ml 
 
Stacking gel 30 % acrylamide mix 1.3 ml 
0.5 M Tris-HCl (pH 6.8) 2.5 ml 
10 % SDS 0.1 ml 
10 % Ammonium persulfate 0.05 ml 
TEMED 0.01 ml 
Distilled water 6.1 ml 
 
PMSF 0.1 M PMSF 174 mg 
Isopropyl alcohol 10 ml 
 
ELISA 
Dulbecco’s PBS KCl 0.2 g 
KH2PO4 0.2 g 
NaCl 8 g 
Na2HPO4 1.15 g 
 
Stop solution ( when 
harvesting cells) 
Fetal bovine serum 20 ml 
Dulbecco’s PBS 80 ml 
 
Coating solution Coating buffer 9. 990 ml 
Coating antibody 10 μl 
 
Detection antibody solution 1X  Assay buffer 5.4956 ml 
Detection antibody 4.4 μl 
 
Streptavidin HRP solution 1X Assay buffer 9.996 ml 
Streptavidin HRP 4 μl 
10 % SDS SDS 10 g 
Distilled water Fill up to a total of 100 ml 
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1X Assay Buffer 5X Assay Buffer 20 ml 
Distilled water 80 ml 
 
Waaler’s PBS (20X) HNa2O4P • 12H2O 792.8 g 
NaH2PO4 * H2O 62.4 g 
NaCl 3240 g 
Distilled water Fill up to a total of 20 l 
 
Wash Buffer Waaler’s PBS 20X 250 ml 
Tween 20 2,5 ml 
Distilled water Fill up to a total of 5 l 
 
Stop Solution H2SO4 22.4 ml 
Distilled water 377.6 ml 
 
Flow cytometry       
Dulbecco’s PBS KCl 0.2 g 
KH2PO4 0.2 g 
NaCl 8 g 
Na2HPO4 1.15 g 
 
Stop solution ( when 
harvesting cells) 
Fetal bovine serum 20 ml 
Dulbecco’s PBS 80 ml 
 
Triton X-100 (10 %) Triton X-100 10 ml 
Distilled water 90 ml 
 
Hoechst 33258 100 µg/ml Hoechst 33258 10 µg/ml 10 µl 
Dulbecco’s PBS 90 µl 
 
DNA staining  Triton X-100 (10 %) 100 µl 
Hoechst 33258 100 µg/ml 100 µl 
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Fluorescence microscopy 
Dulbecco’s PBS KCl 0.2 g 
KH2PO4 0.2 g 
NaCl 8 g 
Na2HPO4 1.15 g 
 
Stop solution ( when 
harvesting cells) 
Fetal bovine serum 20 ml 
Dulbecco’s PBS 80 ml 
 
DNA staining color mix Hoechst 33342 5 mg/ml 100 µl 
Propidium Iodide 100 µl 
 
 
